Skip to main navigation
  • Newsroom
  • Get in Touch
  • LinkedIn
Editas Medicine logo
  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors
  • Newsroom
  • Get in Touch
  • LinkedIn

Media & Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting Materials
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
  • Investor FAQs
  • Contact

Press Releases

Press Releases

Keyword Search

May 18, 2023
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 16, 2023
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 11, 2023
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 5, 2023
Editas Medicine Announces First Quarter 2023 Results and Business Updates
May 1, 2023
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 1, 2023
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
April 27, 2023
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 13, 2023
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
March 8, 2023
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
February 22, 2023
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

>> Main navigation

  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors

©Copyright 2023 Editas Medicine

>> Footer menu

  • Get in Touch
  • Investors
  • Privacy Policy
  • Terms of Use